Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer.

Several reports indicated that aberrant miR-1826 was involved in the initiation and progression of malignancies. However, the clinical significance of miR-1826 in human colorectal cancer (CRC) has not been addressed. The aim of this study was to evaluate the expression and clinical significance of miR-1826 in CRC. We detected miR-1826 expressions by quantitative real.time PCR (qRT-PCR) in 72 CRC tissues, adjacent non.tumor tissues (NATs) and five CRC cell lines, and found that miR-1826 expression in CRC tissues was higher than that in NATs (p<0.05). High miR-1826 expression was significantly associated with some clinicopathologic features such as regional lymph node metastasis (p=0.018), advanced TNM clinical stage (p=0.004), which led to a poor overall survival rate in CRC patients (p=0.032). Our further studies in vitro also demonstrated that miR-1826 inhibitor could effectively suppress the cell proliferation, promote apoptosis and induce G0/G1 cell cycle arrest in CRC cells (p<0.05). Meanwhile, the abilities of cell invasion and migration were effectively suppressed by miR-1826 inhibitor (p<0.05). These findings strongly suggested that miR-1826 played a critical role in the initiation and progression of CRC. Up-regulation of miR-1826 might serve as a novel prognostic marker of CRC and could be a potential target for CRC therapies.